Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
We were quite surprised by the strength of the association between GLP-1 medication use and the lower risk of developing macular degeneration, says Benjamin Young, MD, a corresponding author and an assistant professor of ophthalmology at OHSU Health in Portland, Oregon
In this exclusive segment, Next Health Nashville's Head of Medical, Nathan Byrnes, APNP, and Co-Founder & President, Kevin Peake, share how our proactive functional medicine approach helps prevent disease, optimize wellness, and enhance vitality through cutting-edge treatments like biomarker testing, hormone optimization, hyperbaric oxygen therapy, and much more
LifeWave Stats & Patented Tech Founded in 2004 Open in over 70 countries X39 pre-launched in 2018 with official launch in early 2019 Company growth from 20 million to $600 million (2020-2024) 3,000% growth rate from 2018-2024 Worlds fastest growing direct sales company Our purpose is to empower you to live in the light, maximizing your human potential, with patented life technology that enhances your life. X39 is a fully patented new technology LifeWave patches are an FDA recognized and compliant General Wellness Product Over 80 clinical studies on all the patches Not a me too product like most companies that sell weight loss, supplements, oils, etc
High-performance formulations or clinical applications often demand 99%+ purity, verified by HPLC analysis in the certificate of analysis (CoA)
Abbreviations GLP1-RAs: Glucagon-like peptide-1 receptor agonists FDA: Food Drug Administration EMA: the European Medicines Agency EGDS: Esophagogastroduodenoscopies References NCD Risk Factor Collaboration (NCD-RisC)
